GlassScriptPhysician profile
Joseph L Cvancara
NPI 1548235450
$2,642.28
in general payments reported to CMS, 2019-2025
26 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $104 · 2021: $343 · 2022: $344 · 2023: $593 · 2024: $668 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.50 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.84 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Lilly USA, LLC | $470.61 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $248.55 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $217.38 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $206.45 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $143.42 | 2021-2025 | Ilumya |
| Genzyme Corporation | $93.18 | 2022-2024 | |
| Dermavant Sciences, INC. | $91.13 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $81.20 | 2022-2024 | Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.06 | 2019-2023 | Siliq, Targretin |
| Amgen INC. | $64.68 | 2019-2024 | Otezla |
| Incyte Corporation | $34.59 | 2023 | Opzelura |
| Genentech USA, INC. | $33.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.79 | 2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $33.47 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $29.87 | 2023 | Poteligeo |
| Almirall LLC | $25.00 | 2022 | |
| Verrica Pharmaceuticals INC. | $24.72 | 2023 | Ycanth |
| Leo Pharma INC. | $22.66 | 2025 | Anzupgo |
| Allergan, INC. | $20.01 | 2022 | |
| Strata Skin Sciences, INC. | $18.14 | 2023 | Xtrac |
| Pfizer INC. | $17.31 | 2019 | |
| Celgene Corporation | $17.06 | 2019 | |
| Biofrontera INC. | $13.69 | 2021-2024 | Rhodoled Xl, Ameluz, Xepi |
| Dusa Pharmaceuticals, INC. | $12.33 | 2019 | |
| Biowound Solutions, INC. | $10.27 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cvancara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.